SOURCE: OncoMune

March 03, 2008 14:43 ET

OncoMune Announces Validation of BORIS Target

Recent Findings to Be Reported at AACR Meeting in San Diego

MIAMI, FL--(Marketwire - March 3, 2008) - OncoMune LLC announced positive results demonstrating that the genetic inhibition of BORIS expression leads to programmed cell death of cancer cells. The results will be presented at the upcoming American Association of Cancer Researchers (AACR) Annual Meeting in San Diego, April 12-16 by Dr. Christopher Dougherty, Research Assistant Professor of Biomedical Science at Florida Atlantic University in collaboration with OncoMune.

"OncoMune and collaborators have previously published that the vaccination to the Brother of the Regulator of Imprinted Sites (BORIS) induces immunity to a variety of cancers, including glioma, leukemia, and breast cancer. The current data provides validation at the molecular level that BORIS is not only a marker of cancer cells, but is functionally critical for tumor cell survival," Dr. Dougherty said.

The experiments performed used a process called "RNA interference (RNAi)" to specifically "silence" the expression of BORIS in cancer cells. The results demonstrated that the cancer cells in which the BORIS gene was blocked induced their own death, whereas non-cancer cells treated with the agent that blocks BORIS were unaffected.

"OncoMune has filed several patent applications covering molecular entities capable of inducing RNA interference against BORIS. The scientific acceptance of our work supports the possibility of OncoMune expanding its therapeutic pipeline to include siRNA therapeutics," said Boris Reznik, Chairman of OncoMune.

About OncoMune

OncoMune is an oncology-focused biotechnology company working on targeting the epigenetic cancer causing transcription factor BORIS. BORIS is expressed in all cancer tumors tested to date and not expressed in non-malignant tissue. The company's therapeutics pipeline consists of immunology, small molecule, and genetic-based approaches to destroying cancer cells expressing BORIS.

Contact Information